Epigenomics AG (EPGNY) Stock Analysis
DELISTED
What happened to Epigenomics AG (EPGNY) stock?
Epigenomics AG (EPGNY) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Epigenomics AG (EPGNY). Epigenomics AG is a molecular diagnostics company specializing in non-invasive liquid biopsy tests for early cancer detection. Its flagship product, Epi proColon, screens for colorectal cancer and is available in the United States, Europe, and China.
Last analyzed: Jun 14, 2026Epigenomics AG (EPGNY) Healthcare & Pipeline Overview
Epigenomics AG ADR Information Unsponsored
Epigenomics AG (EPGNY) trades in the U.S. as an American Depositary Receipt (ADR).
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: EPGN
EPGNY OTC Market Information
EPGNY trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy EPGNY shares?
No. EPGNY stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for EPGNY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EPGNY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Epigenomics AG. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.